Figure 2.
Plasma VEGF levels and bevacizumab treatment course. Plasma VEGF-A levels increased during treatment and normalized after bevacizumab was discontinued. Reference value, ≤96.2 pg/mL. IV, intravenous.

Plasma VEGF levels and bevacizumab treatment course. Plasma VEGF-A levels increased during treatment and normalized after bevacizumab was discontinued. Reference value, ≤96.2 pg/mL. IV, intravenous.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal